Skip to main content

Find Clinical Trials

Home
Conditions
ALK Positive Non-small Cell Lung Cancer

Clinical trial condition

ALK Positive Non-small Cell Lung Cancer

Explore clinical trials studying ALK Positive Non-small Cell Lung Cancer. Study availability and eligibility vary by location and protocol.

4 public trials 3 recruiting studies

Refine in advanced search Browse all conditions

ALK Positive Non-small Cell Lung Cancer trial results

Recruiting

AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancer

NCT07617337

Conditions: ALK Positive Non-small Cell Lung Cancer
Locations: Aichi Cancer Center Hospital Nagoya, Aichi-ken, Japan

Kindai University Hospital Sakai, Osaka, Japan

Shizuoka Cancer Center Nagaizumi-cho, Shizuoka, Japan

National Cancer Center Hospital Chuo-ku, Tokyo, Japan

View Trial Details

Recruiting

Study of NXP900 With Lorlatinib in ALK+ Lung Cancer

NCT07784959

Conditions: ALK Positive, ALK Positive Non-small Cell Lung Cancer, ALK+ Non-Small-Cell Lung Carcinoma, +1 more
Locations: NEXT Virginia Fairfax, Virginia, United States

View Trial Details

Recruiting

Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC

NCT06092086

Conditions: ALK Positive Non-small Cell Lung Cancer
Locations: Guangdong Provincial Perople's Hospital Guangzhou, Guangdong, China

View Trial Details

Not yet recruiting

Lorlatinib Plus Sacituzumab Tirumotecan With Peripheral ctDNA Guidance as First-Line Therapy for ALK Fusion-Positive NSCLC

NCT07750704

Conditions: ALK Positive Non-small Cell Lung Cancer
Locations: Guangdong Provincial Perople's Hospital Guangzhou, Guangdong, China

View Trial Details